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Background/Aims: Whether the presence of chronic total occlusion (CTO) affects 
patency after stenting in femoropopliteal lesions is unknown. We determined the 
effects of plain balloon angioplasty (POBA) in comparison with those of stenting 
on patency for femoropopliteal CTO and stenosis (non-CTO).
Methods: We analyzed data from the Korean Vascular Intervention Society Endo-
vascular Therapy in Lower-Limb Artery Diseases Registry, a multicenter cohort of 
patients with lower extremity peripheral arterial disease. Data from 1,329 patients 
and 1558 limbs treated with endovascular intervention for at least one femoropop-
liteal lesion were evaluated.
Results: Among the 1,558 limbs, 345, 432, 275, and 506 were in the non-CTO-PO-
BA, non-CTO-stent, CTO-POBA, and CTO-stent groups, respectively. During 
follow-up, loss of clinical primary patency, a composite of freedom from resteno-
sis or clinically driven target lesion revascularization, occurred in 65 (18.8%), 68 
(15.7%), 62 (22.5%), and 113 limbs (22.3%) in the non-CTO-POBA, non-CTO-stent, 
CTO-POBA, and CTO-stent groups, respectively. The patients in the non-CTO-
stent group showed a significantly better clinical primary patency than those 
in the no-CTO-POBA group, whereas those in the CTO-stent and CTO-POBA 
groups showed no significant differences. After inverse probability of treatment 
weighting to balance the differences among covariates between the non-CTO-
stent and non-CTO-POBA groups, the non-CTO-stent group still showed superi-
or clinical primary patency as compared with the non-CTO-POBA group.
Conclusions: In the patients with femoropopliteal stenosis without CTO, stenting 
resulted in better clinical outcomes than balloon angioplasty. The presence of 
CTO in the femoropopliteal lesion should be considered when selecting a suitable 
device for performing endovascular procedures.
Keywords: Peripheral arterial disease; Registry; Balloon angioplasty; Stent; Coro-
nary occlusion
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INTRODUCTION
Remarkable advances have been made over the last de-
cades in the endovascular treatment of atherosclerotic 
disease in femoropopliteal arteries. Currently, endovas-
cular treatment of femoropopliteal lesions is the first 
choice for stenosis/occlusions < 25 cm [1]. Balloon an-
gioplasty effectively dilates the femoropopliteal lesions 
without any residues. However, the lack of scaffolds of-
ten leads to suboptimal results. Stenting provides a sta-
ble initial success with scaffolds while the high rate of 
stent failure, including stent fracture, thrombosis, and 
restenosis, is still an unresolved concern on the use of 
stents in femoropopliteal lesions. Trials have reported 
contradictory results on the patency of stenting and that 
of isolated plain old balloon angioplasty (POBA) for fem-
oropopliteal occlusive disease. A meta-analysis reported 
that stent placement in femoropopliteal occlusive dis-
ease does not increase the patency rate when compared 
with angioplasty alone at 1 year [2]. Conversely, primary 
stenting with self-expanding nitinol stents for the treat-
ment of superficial femoral artery (SFA) obstructions 
yields a sustained morphological benefit and a trend to-
ward clinical benefit compared with balloon angioplasty 
with optional stenting [3]. In a single-center retrospec-
tive registry, stenting resulted in similar long-term out-
comes as those of POBA when stratified between claudi-
cation and critical limb ischemia [4]. However, stenting 
yielded a statistically better primary patency only in 
the patients with TransAtlantic Inter-Society Consen-
sus classification (TASC-II) C or D lesions. Therefore, 
whether stenting results in a therapeutic benefit as com-
pared with balloon angioplasty remains controversial.
In the present study, we analyzed data from a multi-
center cohort of patients with lower-extremity periph-
eral arterial disease (PAD) who underwent endovascular 
treatment. We determined the effects of POBA in com-
parison with those of stenting on patency for the treat-
ment of femoropopliteal in the presence or absence of 
chronic total occlusion (CTO).
METHODS
Study population
The Korean Vascular Intervention Society Endovascular 
Therapy in Lower-Limb Artery Diseases (K-VIS ELLA) 
registry is a multicenter, observational, retrospective, 
and prospective study of patients with lower extremi-
ty artery diseases treated with endovascular therapy 
(ClinicalTrials.gov NCT02748226). The present study 
used data from the retrospective patient cohort, which 
consists of datasets from 3,073 patients with 3,972 target 
limbs treated between January 2006 and July 2015 in 31 
Korean hospitals [5]. Data regarding the patient base-
line clinical, lesion, and procedural characteristics were 
collected from their electronic medical records. We 
excluded patients who did not receive femoropoplite-
al intervention (Fig. 1). We also excluded patients who 
were treated with drug-coated balloon or drug-eluting 
stents. We divided the patients into 4 groups according 
to the presence of CTO and use of stenting as follows: 
CTO-POBA, patients with CTO treated with POBA; 
CTO-stent, patients with CTO treated with stenting; 
non-CTO-POBA, patients without CTO treated with 
POBA; non-CTO-stent, patients without CTO treated 
with stenting. The study was conducted in accordance 
with the principles of the Declaration of Helsinki and 
approved by the Institutional Review Boards of the 
participating hospitals (Seoul National University Bun-
dang Hospital, B-1603/340-304). The Institutional Review 
Boards of the participating hospitals waived the require-
ment for informed consent for this retrospective study.
Figure 1. Study flow. K-VIS ELLA, the Korean Vascular In-
tervention Society Endovascular Therapy in Lower-Limb 
Artery Diseases; CTO, chronic total occlusion; POBA, plain 
old balloon angioplasty.
K-VIS ELLA registry
From January 2006 through July 2015
(n = 3,073 patients with 3,972 limbs)
70 Intervention with a drug-coated 
     balloon or drug-eluting stent
67 No information regarding the 
    presence of CTO
1,458 Patients with femoropopliteal 
intervention
Patients with femoropopliteal 
intervention with
(n = 1,329 patients and 1,558 limbs)
1,615 Lower extremity intervention 
other than femoropopliteal artery
Patients with CTO 
and POBA (CTO-B)
(n = 240 patients, 
275 limbs)
Patients with CTO 
and stenting (CTO-S)
(n = 439 patients, 
506 limbs)
Patients without CTO 
or stenting (no CTO-S)
(n = 362 patients, 
432 limbs)
Patients without CTO 
and POBA (no CTO-B)
(n = 288 patients, 
345 limbs)
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Definitions
PAD of the lower extremity was defined as the pres-
ence of ≥ 50% narrowing of a lower-extremity artery. 
Claudication was defined as Rutherford category 1, 2, 
or 3 disease (mild, moderate, or severe claudication, 
respectively), and critical limb ischemia was defined 
as Rutherford category 4, 5, or 6 disease (ischemic rest 
pain, minor tissue loss, or major tissue loss, respectively) 
[6]. The presence of hypercholesterolemia was defined 
as a total cholesterol level of > 200 mg/dL or treatment 
with a lipid-lowering agent prior to hospital admission, 
as documented in the medical records. Patients were 
considered current smokers if they smoked at least one 
cigarette per day within the last month. Patients were 
considered ex-smokers if they had stopped smoking at 
least 1 month prior to inclusion in the study. Conges-
tive heart failure was defined as the presence of a left 
ventricular ejection fraction < 40%. Chronic kidney dis-
ease (CKD) was considered to be present if the estimated 
glomerular filtration rate according to the Modification 
of Diet in Renal Disease Study equation was < 60 mL/
min/1.73 m2.
Target vessels were classified as aortoiliac, femoro-
popliteal, anterior tibial, posterior tibial, and peroneal 
arteries. Target lesions of the femoropopliteal arteries 
were classified according to the TASC-II classification 
[7]. Multilevel disease was defined as the presence of sig-
nificant obstructive lesions at > 1 level in the same limb 
(aortoiliac, femoropopliteal, and infrapopliteal). The 
prescribed antiplatelet drugs included aspirin, clopido-
grel, ticlopidine, ticagrelor, prasugrel, and cilostazol.
Endovascular procedure
The crossover or antegrade approach was selected as 
appropriate. Intraluminal or subintimal wire crossing 
was achieved using 0.014- or 0.035-in guidewires at the 
discretion of the operators. Balloon angioplasty with a 
standard balloon was performed in both groups, and 
the maximal diameter of the balloon was recorded. All 
the patients in the stent groups received nitinol stents, 
including Smart Stent (Cordis, Johnson & Johnson, Fre-
mont, CA, USA), Complete SE (Medtronic Inc., Minne-
apolis, MN, USA), or Absolute pro (Abbott, Santa Clara, 
CA, USA). The sum of the stent length and the maximal 
diameter of the stents were recorded. Technical success 
was defined as a residual stenosis of < 30% by final an-
giography. Clinical success was defined as improvement 
in > 1 categories in the Rutherford class after the proce-
dure.
Patient and lesion follow-up
The patients and target lesions were followed up post-
operatively at 6, 12, and 24 months. We examined the re-
sults of the patient’s ankle-brachial index (ABI), duplex 
ultrasonography, computed tomographic angiography, 
and conventional peripheral angiography, which were 
performed at the physician’s discretion during the fol-
low-up period.
End points
The primary end point was clinical primary patency, de-
fined as a composite of freedom from an ABI reduction 
of ≥ 20% or > 0.15 in comparison with the post-inter-
vention ABI, > 50% restenosis, as determined by duplex 
ultrasound (peak systolic velocity ratio < 2.4), computed 
tomographic angiography, or digital subtraction angi-
ography, and freedom from clinically driven target le-
sion revascularization (TLR). Clinically driven TLR was 
adjudicated when the physicians considered reinterven-
tions at the target lesion or if the patient complained 
of exertional limb discomfort or claudication within the 
follow-up period.
The secondary end point consisted of safety end 
points, including the amputation and mortality rates. 
We classified amputations performed above the ankle as 
major amputations. Amputations performed below the 
ankle that did not require the use of prosthesis and did 
not affect walking were defined as minor amputations 
[8,9]. Major bleeding was defined as bleeding that caused 
a decrease in hemoglobin level of ≥ 20 g/L (1.24 mmol/L) 
or that led to transfusion of ≥ 2 units of whole blood or 
red cells [10].
Statistical methods
Continuous variables were expressed as means with 
standard deviations, whereas categorical variables were 
presented as numbers with percentages. Continuous 
variables were compared using the Student t test. Cat-
egorical variables were compared using the chi-square 
test. Survival times were censored at the date of the end 
point or last follow-up. The Kaplan-Meier product-lim-
it estimator and the log-rank test were used to analyze 
1117
 
Chae IH, et al. POBA vs. stenting in fem-pop CTO
www.kjim.orghttps://doi.org/10.3904/kjim.2019.039
continuous survival times, and the mixed-effects Cox 
proportional hazards regression modeling was used to 
test the interaction of treatment assignment and sub-
group factors, as well as multivariate modeling of risk 
factors. Covariates for the adjustment were selected 
using the stepwise Akaike information criterion (AIC) 
method. We included as covariates all the variables 
found to be statistically significant (p < 0.05) in the uni-
variate analysis of the multivariable analysis or variables 
known to be clinically important, excluding those with 
multicollinearity with others. The proportional hazard 
assumption of each variable was tested on the basis of 
Schoenfeld residuals. The model included the avail-
able patient characteristics, clinical risk factors, lesion 
characteristics, and procedural data. To minimize bias 
by indication and missing values, an inverse-probability 
treatment-weighted (IPTW) cohort was created using the 
“twang package” after multiple imputation of missing 
values by the “MICE package” in the R program (The R 
Foundation for Statistical Computing, Vienna, Austria; 
http://www.R-project.org). We provided a pooled re-
sult from 5 different datasets by multiple imputation. 
A two-sided p value of < 0.05 was considered indicative 
of a statistically significant difference. Statistical analy-
ses were performed using R programming version 3.4.2 
(The R Foundation for Statistical Computing). All the 
statistical analyses were performed by a professional 
statistician (S.H.K.).
RESULTS
Patient and lesion characteristics
The baseline demographic and clinical characteristics of 
Table 1. Patients’ baseline characteristics according to the presence of CTO
Characteristic











Age, yr 68.34 ± 8.34 69.48 ± 9.48 0.098 69.08 ± 9.080 69.94 ± 9.94 0.276
Male sex 217 (75.3) 287 (79.3) 0.272 175 (72.9) 369 (84.1) 0.001
BMI, kg/m2 23.95 ± 3.95 23.54 ± 3.54 0.176 23.61 ± 3.61 23.07 ± 3.07 0.083
Hypertension 242 (84.0) 287 (79.3) 0.149 172 (71.7) 319 (72.7) 0.851
DM 224 (77.8) 245 (67.7) 0.006 140 (58.3) 219 (49.9) 0.043
Hypercholesterolemia 110 (38.2) 172 (47.5) 0.021 99 (41.2) 158 (36.0) 0.205
Current smoker 54 (18.8) 96 (26.5) 0.025 67 (27.9) 172 (39.2) 0.004
CHF 21 (7.3) 24 (6.6) 0.861 19 (7.9) 33 (7.5) 0.971
CAD 185 (64.2) 216 (59.7) 0.268 128 (53.3) 238 (54.2) 0.889
CKD 106 (36.8) 84 (23.2) < 0.001 51 (21.2) 66 (15.0) 0.052
Previous stroke 57 (19.8) 50 (13.8) 0.053 37 (15.4) 67 (15.3) > 0.999
Previous bypass surgery 41 (14.2) 33 (9.1) 0.055 15 (6.2) 28 (6.4) > 0.999
Previous amputation 40 (13.9) 14 (3.9) < 0.001 20 (8.3) 18 (4.1) 0.034
Previous PTA 50 (17.4) 47 (13.0) 0.148 33 (13.8) 50 (11.4) 0.438
CLI 131 (45.5) 102 (28.2) < 0.001 102 (42.5) 136 (31.0) 0.003
Aspirin 242 (86.7) 312 (87.2) 0.972 207 (87.7) 375 (87.4) > 0.999
Clopidogrel 231 (82.8) 318 (88.8) 0.038 182 (77.1) 371 (86.5) 0.003
Cilostazol 103 (36.9) 137 (38.3) 0.790 109 (46.2) 198 (46.2) > 0.999
Statin 196 (70.3) 275 (76.8) 0.075 165 (69.9) 299 (69.7) > 0.999
Values are presented as mean ± SD or number (%).
CTO, chronic total occlusion; POBA, plain old balloon angioplasty; BMI, body mass index; DM, diabetes mellitus; CHF, con-
gestive heart failure; CAD, coronary artery disease; CKD, chronic kidney disease; PTA, percutaneous transluminal angioplas-
ty; CLI, critical limb ischemia.
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the patients in the four groups are summarized in Ta-
ble 1. Baseline patient sex and preexisting risk factors 
(body mass index, diabetes, smoking status, and CKD) 
were significantly different between the groups. In ad-
dition, the incidence of critical limb ischemia and pre-
vious amputation were significantly different between 
the groups. Clopidogrel was prescribed at a significant-
lyhigher rate in the stenting group.
Among 1,558 limbs, the numbers of limbs in the non-
CTO-POBA, non-CTO-stent, CTO-POBA, and CTO-
stent were 345, 432, 275, and 506, respectively (Table 2). 
The number of patients with aortoiliac lesion was sig-
nificantly higher in the stent group, whereas that of 
patients with infrapopliteal lesions was higher in the 
POBA group. Lesion characteristics differed between 
the two treatment groups. The mean lesion length was 
longer in the stenting and CTO groups. The maximal 
balloon diameter was significantly larger in the stent-
ing group. The maximal stent diameter was larger and 
the mean stented length was shorter in the non-CTO-
stent group than in the CTO-stent group. Technical and 
clinical successes and good antegrade flow were more 
frequently achieved in the stenting group. The postpro-
cedural target limb ABI did not differ between the two 
groups.
Postprocedural follow-up
The median follow-up duration was 509 days (interquar-
tile range, 246 to 721). The clinical primary patency in 
the non-CTO-stent group was significantly higher than 
that in the non-CTO-POBA group (p = 0.041), whereas it 
did not differ between the CTO-stent and CTO-POBA 
groups (p = 0.670) (Fig. 2A). Freedom from TLR was also 
higher in the non-CTO-stent group than in the non-
CTO-POBA group but showed no significant difference 
between the CTO-POBA and CTO-stent groups (Fig. 2B). 
The estimated clinical primary patency and TLR rates 
are summarized in Supplementary Table 1. Evaluation of 
either the whole population or patients divided accord-
ing to TASC-II classifications (TASC-II A and B vs. C and 
Table 2. Lesion and procedural characteristics according to the presence of CTO
Characteristic
Non-CTO CTO
POBA (n = 345) Stenting (n = 432) p value POBA (n = 275) Stenting (n = 506) p value
ABI target 0.69 ± 0.24 0.64 ± 0.19 0.019 0.58 ± 0.24 0.50 ± 0.20 < 0.001
ABI nontarget 0.78 ± 0.24 0.78 ± 0.23 0.780 0.84 ± 0.27 0.74 ± 0.23 0.001
Aortoiliac lesion 49 (14.2) 115 (26.6) < 0.001 29 (10.5) 157 (31.0) < 0.001
Below-the-knee lesion 202 (58.6) 130 (30.1) < 0.001 126 (45.8) 173 (34.2) 0.002
Lesion length, mm 127.97 ± 105.80 136.02 ± 106.23 0.318 159.70 ± 103.38 198.94 ± 108.86 < 0.001
Maximal balloon diameter, mm 5.28 ± 1.22 5.51 ± 2.06 0.057 5.20 ± 0.96 5.68 ± 2.82 0.001
Balloon length, mm 166.75 ± 147.79 117.16 ± 107.55 < 0.001 156.65 ± 130.29 141.59 ± 110.34 0.134
Max stent diameter, mm 6.97 ± 4.25 6.75 ± 0.84
Stent length sum, mm 102.94 ± 59.17 152.62 ± 85.11
Technical success < 0.001 < 0.001
No 3 (0.9) 10 (2.4) 26 (9.6) 14 (2.8)
Suboptimal 32 (9.4) 6 (1.4) 30 (11.1) 21 (4.2)
Yes 304 (89.7) 409 (96.2) 214 (79.3) 466 (93.0)
Good antegrade flow 334 (98.5) 413 (97.2) 0.313 239 (88.5) 477 (95.2) 0.001
Residual stenosis, < 30% 305 (90.0) 415 (97.6) < 0.001 216 (80.0) 472 (94.2) < 0.001
Contrast volume, mL 156.26 ± 78.84 159.05 ± 97.70 0.702 183.38 ± 88.95 185.30 ± 3.52 0.814
Clinical success 197 (57.1) 323 (74.8) < 0.001 139 (50.5) 340 (67.2) < 0.001
Post-ABI 0.82 ± 0.22 0.87 ± 0.18 0.038 0.84 ± 0.25 0.84 ± 0.19 0.836
Values are presented as mean ± SD or number (%).
CTO, chronic total occlusion; POBA, plain old balloon angioplasty; ABI, ankle-brachial index.
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D) did not result in any difference in outcome between 
stenting or the POBA procedures (Supplementary Ta-
bles 2-5, Supplementary Figs. 1 and 2).
We performed a Cox proportional hazard analysis to 
identify and adjust covariates, which may have affected 
the clinical primary patency rate. Hypercholesterolemia 
and lesion length were significantly associated with the 
clinical primary patency rate in both groups, whereas 
chronic renal failure was differentially associated with 
the outcome of CTO and non-CTO lesions. Even after 
adjustment with the covariates, stenting was associated 
with a better clinical primary patency than balloon an-
gioplasty only in the non-CTO lesion group (Table 3).
With regard to the unbalanced baseline characteristics 
between the POBA and stenting groups, we performed 
IPTW analyses to test a causal inference from our ret-
rospective data. Most covariates were well balanced af-
ter IPTW except for chronic renal failure, critical limb 
ischemia, and below-the-knee lesion in the non-CTO 
group (Table 4). We found that stenting in the non-
CTO group led to a better clinical primary patency and 
freedom from TLR than did the POBA treatment in the 
non-CTO group in the IPTW analysis (p = 0.05 and p = 
0.034, respectively) and in the adjustments for chronic 
renal failure, critical limb ischemia, and below-the-knee 
lesion (hazard ratio [HR], 1.43 [1.08 to 1.91]; p = 0.014; HR, 
1.61 [1.15 to 2.26]; p = 0.006, respectively) (Fig. 3). However, 
in the CTO group, no significant difference was found 
between the treatment groups.
 
Sensitivity analyses
Several sensitivity analyses were performed to verify the 
robustness of the results using exploratory subgroups, 
including (1) de novo lesion only after the exclusion of a 
previously treated lesion, (2) technical success only after 
the exclusion of technical failure, and (3) good antegrade 
flow after the procedure. In any subgroup analysis, 
stenting in the non-CTO group led to a better clinical 
primary patency and freedom from TLR than did POBA 
in the non-CTO group (Supplementary Figs. 3-5).
DISCUSSION
In the present study, we determined for the first time 
the effects of POBA in comparison with those of stent-
ing on clinical primary patency in patients with fem-
oropopliteal CTO and non-CTO lesions. The non-
CTO-stent group showed a significantly better clinical 
primary patency than the no-CTO-POBA group, where-
Figure 2. Kaplan-Meier curves for outcomes. Kaplan-Meier curves for clinical primary patency and target vessel revascular-
ization in non-the chronic total occlusion (CTO) and CTO groups. (A) Clinical primary patency, (B) freedom from target lesion 
revascularization (TLR). BMS, bare metal stent; POBA, plain old balloon angioplasty.
Clinical primary patency
Non-CTO
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as the CTO-stent and CTO-POBA groups showed no 
significant difference in the crude population. After the 
IPTW analysis to balance the difference of covariates be-
tween the non-CTO-stent and non-CTO-POBA groups, 
the non-CTO-stent group still showed superior clinical 
primary patency as compared with the non-CTO-POBA 
group. Sensitivity analyses also showed robustness of 
the results in the various subgroups.
Comparison between balloon angioplasty and stenting
Clinical studies have shown the superiority of stenting 
to POBA in long SFA lesions [11,12], whereas in the short 
lesions (< 10 cm in length) no significant differences 
were found [13]. A previous meta-analysis showed that 
a short-term but no long-term benefit of primary pa-
tency from the primary stenting of SFA lesions in ad-
dition to angioplasty [14]. However, most studies were 
underpowered to sufficiently discriminate the efficacy 
of stenting in the CTO and non-CTO groups, and in-
cluded patients with total occlusions comprising < 30% 
of the whole study population. Therefore, we do not 
have any data regarding the impact of CTO when decid-
ing treatment options for SFA lesions. SFA is subject to 
longitudinal stretching, external compression, torsion, 
and flexion, which may lead to stent fractures and even-
tually restenosis. Therefore, understanding and identi-
fying conditions in which stenting is superior to POBA 
are important. We demonstrated for the first time that 
stenting resulted in better clinical primary patency and 
was inferior to POBA only in the non-CTO lesion group, 
with a power of 80%. Lesion length was also a significant 
predictor of clinical primary patency irrespective of the 
Table 4. Characteristics according to the presence of CTO after inverse probability treatment weighting
Characteristic
Non-CTO CTO
Stenting POBA SMD p value Stenting POBA SMD p value
Age, yr 69.77 ± 8.52 69.39 ± 8.78 0.044 0.850 69.81 ± 9.45 69.57 ± 9.72 0.026 0.946
Male sex 502 (76.83) 473 (76.13) 0.017 0.829 565 (82.39) 462 (77.57) 0.127 0.118
BMI, kg/m2 23.64 ± 3.76 23.73 ± 3.60 0.022 0.726 23.26 ± 3.73 23.37 ± 3.93 0.029 0.874
HTN 308 (47.21) 262 (42.25) 0.099 0.197 261 (38.03) 251 (42.14) 0.085 0.317
DM 459 (70.32) 461 (74.26) 0.086 0.268 351 (51.18) 327 (54.85) 0.073 0.387
Hypercholesterolemia 308 (47.21) 262 (42.25) 0.099 0.197 261 (38.03) 251 (42.14) 0.085 0.317
CRF 162 (24.80) 202 (32.46) 0.177 0.028 109 (15.87) 95 (16.00) 0.004 0.963
CHF 46 (6.97) 45 (7.24) 0.011 0.892 52 (7.56) 37 (6.19) 0.052 0.470
Smoking 172 (26.32) 121 (19.43) 0.157 0.180 267 (38.97) 206 (34.55) 0.091 0.293
CAD 386 (59.11) 407 (65.51) 0.130 0.089 377 (54.98) 338 (56.72) 0.035 0.675
Stroke 91 (13.98) 110 (17.75) 0.109 0.180 112 (16.38) 88 (14.80) 0.043 0.611
CLI 187 (28.66) 225 (36.24) 0.168 0.034 221 (32.31) 189 (31.69) 0.013 0.869
Lesion length, cm 13.13 ± 10.21 12.94 ± 10.41 0.019 0.482 19.09 ± 11.00 17.45 ± 10.86 0.149 0.249
TASC 0.516 0.774
A 150 (22.97) 136 (21.84) 0.027 58 (8.51) 48 (8.01) 0.018
B 206 (31.57) 221 (35.56) 0.086 77 (11.26) 76 (12.78) 0.048
C 224 (34.23) 185 (29.80) 0.094 161 (23.46) 156 (26.15) 0.063
D 73 (11.22) 79 (12.80) 0.050 389 (56.77) 316 (53.06) 0.075
Aortoiliac lesion 0.64 ± 0.21 0.68 ± 0.23 0.176 0.169 0.50 ± 0.22 0.55 ± 0.22 0.212 0.260
Below-the-knee lesion 239 (36.61) 302 (48.62) 0.249 0.002 242 (35.35) 256 (42.89) 0.158 0.065
Values are presented as mean ± SD or number (%). Inverse probability treatment weighting with age, sex, BMI, DM, chronic 
kidney disease, previous amputation, CLI, aortoiliac lesion, below-the-knee lesion, lesion length, maximal balloon diameter.
CTO, chronic total occlusion; POBA, plain old balloon angioplasty; SMD, starndardized mean difference; BMI, body mass 
index; HTN, hypertension; DM, diabetes mellitus; CRF, chronic renal failure; CHF, congestive heart failure; CAD, coronary 
artery disease; CLI, critical limb ischemia; TASC, TransAtlantic Inter-Society Consensus classification.
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presence of CTO in the multivariate Cox proportional 
hazard analyses. The TASC-II classification is a sophis-
ticated system used to predict patency depending on the 
lesion length, location, and presence of CTO. However, 
we found that the TASC-II classification could predict 
long-term clinical primary patency but could not differ-
entiate any benefit of stenting over POBA for the SFA 
lesions in our study.
Comparison between CTO and stenosis
A previous study that investigated the endovascular 
management of SFA CTO resulted in a reasonable pri-
mary patency ranging from 44% to 58% and a second-
ary patency of 92% [15]. In line with our results, no sig-
nificant differences were found among the treatment 
modalities (angioplasty, angioplasty with stenting, and 
atherectomy). The inability to cross all lesions intralu-
minally in SFA occlusions may have led to a high rate of 
subintimal wiring and complications such as perfora-
tion or dissection. The procedural complexity in the oc-
cluded cases potentially worsened the clinical outcomes 
in the stenting group, which inevitably included bailout 
stenting. In a study where stenting was compared with 
angioplasty only in patients with chronic occlusive dis-
ease treated with subintimal angioplasty, 1-year primary 
patency was not significantly different between the stent 
and no-stent groups [16].
Stenting or not: lesion or clinical indicators
In a randomized controlled trial (RCT) that reported 
the benefit of stenting over balloon angioplasty, the oc-
clusion rate was 31% in the angioplasty group and 41% 
in the stenting group [3]. In our real-world registry, the 
occlusion rate was 50%, which was significantly high-
er than in the RCT. The overall stenting efficacy was 
not different from that of POBA. Therefore, stenting 
might be recommended only for cases of stenotic SFA 
lesions. The clinical status may also affect the efficacy 
of treatment modalities. For example, in CLI patients 
with SFA CTOs, atherectomy was reported to produce 
better outcomes than angioplasty alone [15]. The authors 
also reported that CTOs treated with stenting improved 
secondary patency rates as compared with those treat-
ed with POBA in patients with diabetes. In addition to 
CTO, CLI, and diabetes mellitus, additional lesion or 
clinical characteristics need to be identified to warrant 
the decision of stenting.
Future strategies
Endovascular therapies superior to POBA or bare-met-
Figure 3. Kaplan-Meier curves for outcomes after inverse probability of treatment weighting. Kaplan-Meier curves for clinical 
primary patency and target vessel revascularization in the non-chronic total occlusion (CTO) and CTO groups. (A) Clinical 
primary patency, (B) freedom from target lesion revascularization (TLR). HR, hazard ratio; CI, confidence interval;  BMS, bare 
metal stent; POBA, plain old balloon angioplasty.
Clinical primary patency
Non-CTO
Long-rank test p = 0.081
Adjusted HR, 1.43; 95% CI, 1.08–1.91; p = 0.041
Long-rank test p = 0.796
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al stenting have recently attracted considerable interest. 
Paclitaxel-eluting stents (PES) displayed sustained safe-
ty and efficacy compared with POBA in patients with 
femoral artery disease, with superior clinical efficacy as 
compared with POBA and provisional stenting [17]. In 
addition, paclitaxel-coated balloon angioplasty (PEB) 
for atherosclerotic femoropopliteal disease reduces 
target-lesion revascularization to a greater degree than 
POBA, with the advantage of leaving no prosthetic ma-
terial behind [18-20]. However, decision-making criteria 
on whether to apply PES or PEB remain to be investigat-
ed. Whether PEB angioplasty and stenting may further 
reduce restenosis and improve long-term clinical out-
comes as compared with PEB angioplasty alone in SFA 
occlusion deserves further investigation. Drug-eluting 
stents do not seem to be an option for SFA occlusions 
because a recent registry showed that PES did not im-
prove outcomes as compared with bare-metal stents in 
TASC-II C and D femoropopliteal lesions [21].
Limitations
The present data do not represent the results of a ran-
domized controlled study but instead are derived from 
a multicenter registry. Consequently, risk factors such 
as diabetes mellitus and critical limb ischemia showed 
a non-uniform distribution between the groups. Al-
though we adjusted for significant risk factors, un-
measured covariates may have influenced the study 
outcomes. In our registry, we could not differentiate 
percutaneous transluminal angioplasty with provision-
al stenting from primary stenting. As an initial strategy, 
the 2 treatment options have different implications for 
operators in terms of procedure planning and may lead 
to different clinical outcomes. Our results reflect the 
clinical outcomes of the endovascular procedure ulti-
mately chosen by the operators, although it is difficult to 
separate POBA from stenting because the femoropopli-
teal lesion is usually very long and treated with mixed 
methods.
In conclusion, in patients with femoropopliteal steno-
sis without CTO, stenting demonstrated better clinical 
outcomes than balloon angioplasty. The presence of CTO 
in femoropopliteal lesions should be considered when 
selecting a device to be used in endovascular procedures.
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       Supplementary Table 1. Estimated clinical primary patency and target lesion revascularization rate with 95% CI
Variable Non-CTO-POBA Non-CTO-Stenting CTO-POBA CTO-Stenting
Estimated clinical primary patency rate with 95% CI (%)
1 yr 84.2 (80.1–88.5) 89.6 (86.6–92.8) 83.7 (79.2–88.5) 83.9 (80.5–87.5)
2 yr 79.5 (74.7–84.6) 84.5 (80.7–88.6) 76.1 (70.5–82.1) 77.1 (72.9–81.5)
3 yr 74.7 (68.4–81.5) 80.4 (75.6–85.5) 66.8 (58.7–76.1) 67.4 (61.6–73.7)
4 yr 69.3 (61.4–78.3) 77.7 (72.2–83.6) 64.2 (55.2–74.7) 62.7 (55.9–70.4)
5 yr 65.0 (55.8–75.6) 71.2 (64.1–79.2) 64.2 (55.2–74.7) 61.3 (54.2–69.3)
Estimated target lesion revascularization rate with 95% CI (%)
1 yr 88.5 (84.8–92.3) 93.0 (90.4–95.7) 89.9 (86.2–93.9) 89.0 (86.0–92.0)
2 yr 82.8 (78.2–87.7) 89.7 (86.4–93.1) 85.8 (81.2–90.7) 82.5 (78.7–86.5)
3 yr 80.4 (74.9–86.3) 86.1 (81.7–90.7) 76.9 (69.2–85.3) 73.6 (68.0–79.6)
4 yr 78.7 (72.5–85.4) 82.4 (77.0–88.1) 74.8 (66.6–84.1) 68.1 (61.4–75.6)
5 yr 74.4 (66.5–83.3) 74.9 (67.6–82.9) 74.8 (66.6–84.1) 65.4 (58.1–73.6)
CI, confidence interval; CTO, chronic total occlusion; POBA, plain old balloon angioplasty.
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Supplementary Table 2. Patients’ baseline characteristics in the whole population
Characteristic POBA (n = 528) Stenting (n = 801) p value
Age 68.68 ± 8.68 69.73 ± 9.73 0.043
Male sex 392 (74.2) 656 (81.9) 0.001
BMI 23.80 ± 3.80 23.28 ± 3.28 0.017
Hypertension 414 (78.4) 606 (75.7) 0.273
DM 364 (68.9) 464 (57.9) < 0.001
Hypercholesterolemia 209 (39.6) 330 (41.2) 0.596
Current smoker 121 (22.9) 268 (33.5) < 0.001
CHF 40 (7.6) 57 (7.1) 0.836
CAD 313 (59.3) 454 (56.7) 0.377
CKD 157 (29.7) 150 (18.7) < 0.001
Previous stroke 94 (17.8) 117 (14.6) 0.138
Previous bypass surgery 56 (10.6) 61 (7.6) 0.074
Previous amputation 60 (11.4) 32 (4.0) < 0.001
Previous PTA 83 (15.7) 97 (12.1) 0.072
CLI 233 (44.1) 238 (29.7) < 0.001
Aspirin 449 (87.2) 687 (87.3) > 0.999
Clopidogrel 413 (80.2) 689 (87.5) < 0.001
Cilostazol 212 (41.2) 335 (42.6) 0.657
Statin 361 (70.1) 574 (72.9) 0.294
Values are presented as mean ± SD or number (%).
POBA, plain old balloon angioplasty; BMI, body mass index; DM, diabetes mellitus; CHF, congestive heart failure; CAD, coro-
nary artery disease; CKD, chronic kidney disease; PTA, percutaneous transluminal angioplasty; CLI, critical limb ischemia.
www.kjim.org
Chae IH, et al. POBA vs. stenting in fem-pop CTO
https://doi.org/10.3904/kjim.2019.039
       Supplementary Table 3. Lesion and procedural characteristics in the whole population 
Characteristic POBA (n = 620) Stenting (n = 938) p value
ABI target 0.64 ± 0.64 0.57 ± 0.57 < 0.001
ABI nontarget 0.81 ± 0.26 0.76 ± 0.23 0.008
Aortoiliac lesion 78 (12.6) 272 (29.0) < 0.001
Below-the-knee lesion 126 (45.8) 173 (34.2) 0.002
Diameter stenosis, % 89.40 ± 12.62 92.44 ± 11.28 < 0.001
Lesion length, mm 141.80 ± 105.84 169.79 ± 112.08 < 0.001
Maximal balloon diameter, mm 5.24 ± 1.12 5.60 ± 2.49 0.003
Balloon length, mm 162.48 ± 140.62 130.11 ± 109.66 < 0.001
Max stent diameter, mm 6.85 ± 2.94
Stent length sum, mm 129.86 ± 78.34
Technical success < 0.001
   No 29 (4.8) 24 (2.6)
   Sub-optimal 62 (10.2) 27 (2.9)
   Yes 518 (85.1) 875 (94.5)
Good antegrade flow 573 (94.1) 890 (96.1) 0.087
Residual stenosis, < 30% 521 (85.6) 887 (95.8) < 0.001
Contrast volume, mL 168.19 ± 84.42 172.78 ± 96.36 0.396
Clinical success 336 (54.2) 663 (70.7) < 0.001
Post-ABI 0.83 ± 0.23 0.85 ± 0.18 0.133
Values are presented as mean ± SD or number (%).
POBA, plain old balloon angioplasty; ABI, ankle-brachial index.
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Supplementary Table 4. Patients baseline characteristics according to TASC II AB vs. CD 
Characteristic











Age 67.72 ± 7.72 69.53 ± 9.53 0.027 69.39 ± 9.39 69.85 ± 9.85 0.499
Male sex 173 (76.9) 239 (83.0) 0.107 219 (72.3) 417 (81.3) 0.004
BMI 23.93 ± 3.93 23.46 ± 3.46 0.165 23.70 ± 3.70 23.18 ± 3.18 0.067
Hypertension 188 (83.6) 228 (79.2) 0.252 226 (74.6) 378 (73.7) 0.840
DM 175 (77.8) 176 (61.1) < 0.001 189 (62.4) 288 (56.1) 0.094
Hypercholesterolemia 102 (45.3) 148 (51.4) 0.203 107 (35.3) 182 (35.5) > 0.999
Current smoker 49 (21.8) 79 (27.4) 0.172 72 (23.8) 189 (36.8) < 0.001
CHF 13 (5.8) 24 (8.3) 0.348 27 (8.9) 33 (6.4) 0.241
CAD 145 (64.4) 179 (62.2) 0.659 168 (55.4) 275 (53.6) 0.662
CKD 77 (34.2) 67 (23.3) 0.008 80 (26.4) 83 (16.2) 0.001
Previous stroke 43 (19.1) 51 (17.7) 0.770 51 (16.8) 66 (12.9) 0.145
Previous bypass surgery 33 (14.7) 26 (9.0) 0.065 23 (7.6) 35 (6.8) 0.786
Previous amputation 23 (10.2) 9 (3.1) 0.002 37 (12.2) 23 (4.5) < 0.001
Previous PTA 27 (12.0) 31 (10.8) 0.766 56 (18.5) 66 (12.9) 0.038
CLI 97 (43.1) 66 (22.9) < 0.001 136 (44.9) 172 (33.5) 0.002
Aspirin 196 (90.7) 258 (92.5) 0.597 253 (84.6) 429 (84.4) > 0.999
Clopidogrel 184 (85.2) 249 (89.2) 0.224 229 (76.6) 440 (86.6) < 0.001
Cilostazol 80 (37.0) 107 (38.4) 0.837 132 (44.1) 228 (44.9) 0.897
Statin 168 (77.8) 211 (75.6) 0.650 193 (64.5) 363 (71.5) 0.049
Values are presented as mean ± SD or number (%).
TASC, TransAtlantic Inter-Society Consensus classification; POBA, plain old balloon angioplasty; BMI, body mass index; DM, 
diabetes mellitus; CHF, congestive heart failure; CAD, coronary artery disease; CKD, chronic kidney disease; PTA, percutane-
ous transluminal angioplasty; CLI, critical limb ischemia.
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      Supplementary Table 5. Lesion and procedural characteristics according to the presence of chronic total occlusion
Characteristic
TASC (A, B) (n = 781) TASC (C, D)
POBA (n = 262) Stenting (n = 333) p value POBA (n = 358) Stenting (n = 605) p value
ABI target 0.72 ± 0.26 0.64 ± 0.20 0.001 0.58 ± 0.22 0.52 ± 0.20 0.001
ABI nontarget 0.85 ± 0.25 0.81 ± 0.21 0.126 0.78 ± 0.26 0.73 ± 0.24 0.035
Aortoiliac lesion 36 (13.7) 83 (24.9) 0.001 42 (11.7) 189 (31.2) < 0.001
Below-the-knee lesion 142 (54.2) 87 (26.1) < 0.001 186 (52.0) 216 (35.7) < 0.001
TASC 0.166 0.916
A 100 (38.2) 147 (44.1)
B 162 (61.8) 186 (55.9)
C 163 (45.5) 272 (45.0)
D 195 (54.5) 333 (55.0)
Diameter stenosis, % 83.49 ± 13.28 86.43 ± 13.22 0.007 93.73 ± 10.14 95.75 ± 8.40 0.002
Lesion length, cm 81.05 ± 65.05 84.96 ± 57.43 0.470 186.35 ± 107.87 216.02 ± 107.49 < 0.001
Maximal balloon diameter, mm 5.18 ± 1.35 5.51 ± 2.27 0.035 5.29 ± 0.90 5.65 ± 2.61 0.003
Balloon length, mm 147.30 ± 36.51 109.81 ± 107.24 0.001 174.12 ± 142.82 141.44 ± 109.45 0.001
Max stent diameter, mm 6.79 ± 3.23 6.89 ± 2.78
Stent length sum, mm 100.65 ± 56.57 145.17 ± 83.67
Technical success 0.001 < 0.001
No 4 (1.6) 5 (1.5) 25 (7.1) 19 (3.2)
Sub-optimal 29 (11.3) 11 (3.3) 33 (9.4) 16 (2.7)
Yes 224 (87.2) 315 (95.2) 294 (83.5) 560 (94.1)
Good antegrade flow 248 (96.5) 321 (97.0) 0.927 325 (92.3) 569 (95.6) 0.047
Residual stenosis, < 30% 228 (88.7) 322 (97.3) < 0.001 293 (83.2) 565 (95.0) < 0.001
Contrast volume, mL 162.85 ± 8.32 156.81 ± 102.70 0.497 172.26 ± 81.26 182.91 ± 90.78 0.125
Clinical success 145 (55.3) 241 (72.4) < 0.001 191 (53.4) 422 (69.8) < 0.001
Post-ABI 0.88 ± 0.21 0.89 ± 0.17 0.554 0.79 ± 0.24 0.83 ± 0.19 0.082
Values are presented as mean ± SD or number (%).
TASC, TransAtlantic Inter-Society Consensus classification; POBA, plain old balloon angioplasty; ABI, ankle-brachial index.
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Supplementary Figure 1. (A) Clinical primary patency. (B) Target lesion revascularization.  BMS, bare metal stent; POBA, plain 
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      Supplementary Figure 2. Kaplan-Meier curves for outcomes according to TransAtlantic Inter-Society Consensus classifica-
tion (TASC) AB vs. CD. (A) Clinical primary patency. (B) Clinical primary patency. (C) Freedom from target lesion revascular-
ization (TLR). (D) Freedom from TLR. BMS, bare metal stent; POBA, plain old balloon angioplasty. 
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TASC CDTASC AB





















































































































































       
www.kjim.org
 The Korean Journal of Internal Medicine. Vol. 35, No. 5, September 2020
https://doi.org/10.3904/kjim.2019.039
Supplementary Figure 3. Kaplan-Meier curves for outcomes in various subgroups: de novo lesion only. (A) Clinical primary pa-
tency, (B) target lesion revascularization. CB, patient group with chronic total occlusion treated by plain balloon angioplasty; 
CS, patient group with chronic total occlusion treated by stenting; SB, patient group without chronic total occlusion treated 
by plain balloon angioplasty; SS, patient group without chronic total occlusion treated by stenting. 
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      Supplementary Figure 4. Kaplan-Meier curves for outcomes in various subgroups: technical success only. (A) Clinical primary 
patency, (B) target lesion revascularization. CB, patient group with chronic total occlusion treated by plain balloon angioplas-
ty; CS, patient group with chronic total occlusion treated by stenting; SB, patient group without chronic total occlusion treat-
ed by plain balloon angioplasty; SS, patient group without chronic total occlusion treated by stenting. 
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Supplementary Figure 5. Kaplan-Meier curves for outcomes in various subgroups: good antegrade flow only. (A) Clinical pri-
mary patency, (B) target lesion revascularization. CB, patient group with chronic total occlusion treated by plain balloon an-
gioplasty; CS, patient group with chronic total occlusion treated by stenting; SB, patient group without chronic total occlusion 
treated by plain balloon angioplasty; SS, patient group without chronic total occlusion treated by stenting. 













































0.5 1 1.5 2 2.5 3
239
476
334
413
0.570
0.337
0.006 0.070
0.610
0.011
147
289
193
274
89
186
124
167
28
73
43
96
CB
CS
SB
SS
CB
CS
SB
SS
p values vs.
CS CS SB
p = 0.027
p = 0.028
0.228
0.501
0.207 0.033
0.587
0.004
CB
CS
SB
SS
p values vs.
CS CS SB
239
476
334
413
159
302
202
281
101
198
131
176
36
81
51
103
CB
CS
SB
SS
A B
